Publications & Presentations ENDO 2026: Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman PrimatesJune 16, 2026Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with ObesityJune 5, 2026The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectivesMarch 11, 2026Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Obese PrimatesDecember 2, 2025Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjectsMay 20, 2023Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in ratsMay 20, 2023Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2023Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogsMay 20, 2021
ENDO 2026: Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman PrimatesJune 16, 2026
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with ObesityJune 5, 2026
The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectivesMarch 11, 2026
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Obese PrimatesDecember 2, 2025
Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024
Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023
Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjectsMay 20, 2023
Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in ratsMay 20, 2023
Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2023
